Skip to content
Search

Latest Stories

All pharmacy system suppliers in Wales now support EPS

Electronic prescribing service (EPS) in Wales
pharmacist with digital tablet checking prescription(gettyimages)

Since the launch of EPS in November 2023, more than 700,000 prescription items have been dispensed using the service in Wales

Three more pharmacy system suppliers have received approval to roll out their software in community pharmacies to support electronic prescribing service (EPS) in Wales.

The approval means all seven pharmacy system suppliers who have contracts with pharmacies in Wales can now deliver EPS.


Digital Health and Care Wales (DHCW) announced on 17 January 2025 that healthcare technology firms Cegedim Rx, EMIS and PharmacyX have successfully developed and tested systems capable of handling electronic prescriptions.

“Following robust monitoring, any pharmacy using the suppliers' software will be able to use EPS, providing they have completed a number of readiness activities,” DHCW stated.

System suppliers Invatech, Boots, Positive Solutions and Clanwilliam completed testing of their software systems last year.

Apotec is currently undergoing the assurance process, according to DHCW.

This development marks a significant milestone in DHCW’s aim to move from a paper-based prescription process to a digital system.

“EPS makes things easier, safer and more efficient for patients and healthcare staff, as well as helping the environment as it reduces the amount of paper we print,” the organisation noted.

Jenny Pugh-Jones, programme oversight chair for the primary care EPS programme at DHCW, highlighted the collaborative efforts among suppliers, EPS programme team, community pharmacies, GP practices and other partners in achieving this milestone.

“EPS brings a number of benefits to patients in Wales, and I’m delighted it will now reach more areas in the coming months,” she said.

Since the launch of EPS in November 2023, more than 700,000 prescription items have been dispensed via the service, according to DHCW. The service is currently available in 25 GP practices and more than 150 pharmacies across Wales.

Testing of Pharmacy Systems

EMIS’s ProScript Connect pharmacy system was tested at the G. Rowe pharmacies in Nantymoel and Ogmore Vale, Bridgend, in partnership with Nantymoel Surgery.

The software can be used at pharmacies using ProScript Connect as well as those that have a contract with AAH.

Sima Jassal, clinical director of pharmacy at EMIS, commented: “Delivering the Electronic Prescription Service to our ProScript Connect users across Wales is another important step forwards for community pharmacy - making dispensing more efficient and safer for patients.”

PharmacyX, the only Wales-based pharmacy system to achieve EPS accreditation, tested its software at Health Plus Pharmacy in Blaenavon in collaboration with Blaenavon Medical Practice.

Pharmacy X Director Paul Mayberry stated: “As a homegrown solution, PharmacyX is uniquely positioned to meet the needs of Welsh pharmacies, and we look forward to supporting their journey into this exciting digital future.”

Cegedim Rx’s Pharmacy Manager software was tested at two branches of Nelson’s Pharmacy in Tredegar, Blaenau Gwent.

Cegedim Rx managing director Tracey Robertson remarked: “The benefits of the EPS programme are far reaching. It enables pharmacies and GP practices to work more efficiently, while also enabling patients to easily and conveniently access the care they need.”

EPS is a key part of the Digital Medicines transformation programme, managed by DHCW.

All system suppliers are supported by the Community Pharmacy System Innovation Fund, established by Life Sciences Hub Wales (LSHW) and Digital Medicines on behalf of the Welsh Government.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less